-
INOVIQ has settled the legal proceeding related to the BARD1 performance shares
-
Plaintiffs to receive BARD1 Lung Cancer Test IP and $1 million payment. INOVIQ retains Breast and Ovarian Cancer IP and receives 10% of future sales of BARD1 Lung Cancer Test until the expiry of relevant patents, and 5% thereafter
-
Legal Proceeding by Plaintiffs will be dismissed in accordance with agreed Court orders and no costs awarded
Melbourne, Australia, 28 November 2022: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) advisesthat a settlement has been reached between INOVIQ and the Plaintiffs (together Tony Walker and former Executive Director and Chief Scientific Officer Dr Irmgard Irminger-Finger) related to its claim against INOVIQ announced to ASX on 24 February 2021.
For more information, download the attached PDF.
Download this document
